

Raw Sequence Listing Error Summary

[illegible]

SERIAL NUMBER: 09/825,517

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

- | | | |
|----|---------------------------------------|---|
| 1 | _____ Wrapped Nucleics | <p>The number/text at the end of each line "wrapped" down to the next line.
 This may occur if your file was retrieved in a word processor after creating it.
 Please adjust your right margin to .3, as this will prevent "wrapping".</p> |
| 2 | _____ Wrapped Aminos | <p>The amino acid number/text at the end of each line "wrapped" down to the next line.
 This may occur if your file was retrieved in a word processor after creating it.
 Please adjust your right margin to .3, as this will prevent "wrapping".</p> |
| 3 | _____ Incorrect Line Length | <p>The rules require that a line not exceed 72 characters in length. This includes spaces.</p> |
| 4 | _____ Misaligned Amino Acid Numbering | <p>The numbering under each 5th amino acid is misaligned. This may be caused by the use of tabs between the numbering. It is recommended to delete any tabs and use spacing between the numbers.</p> |
| 5 | _____ Non-ASCII | <p>This file was not saved in ASCII (DOS) text, as required by the Sequence Rules.
 Please ensure your subsequent submission is saved in ASCII text so that it can be processed.</p> |
| 6 | _____ Variable Length | <p>Sequence(s) _____ contain n's or Xaa's which represented more than one residue.
 As per the rules, each n or Xaa can only represent a single residue.
 Please present the maximum number of each residue having variable length and indicate in the (ix) feature section that some may be missing.</p> |
| 7 | _____ PatentIn ver. 2.0 "bug" | <p>A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequence(s) _____. Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies primarily to the mandatory <220>-<223> sections for Artificial or Unknown sequences.</p> |
| 8 | _____ Skipped Sequences (OLD RULES) | <p>Sequence(s) _____ missing. If intentional, please use the following format for each skipped sequence:
 (2) INFORMATION FOR SEQ ID NO:X:
 (i) SEQUENCE CHARACTERISTICS:(Do not insert any headings under "SEQUENCE CHARACTERISTICS")
 (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X:
 This sequence is intentionally skipped</p> <p>Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s).</p> |
| 9 | _____ Skipped Sequences (NEW RULES) | <p>Sequence(s) _____ missing. If intentional, please use the following format for each skipped sequence.
 <210> sequence id number
 <400> sequence id number
 000</p> |
| 10 | _____ Use of n's or Xaa's (NEW RULES) | <p>Use of n's and/or Xaa's have been detected in the Sequence Listing.
 Use of <220> to <223> is MANDATORY if n's or Xaa's are present.
 In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.</p> |
| 11 | _____ Use of "Artificial" (NEW RULES) | <p>Use of "Artificial" only as "<213> Organism" response is incomplete, per 1.823(b) of New Sequence Rules.
 Valid response is Artificial Sequence.</p> |
| 12 | _____ Use of <220>Feature (NEW RULES) | <p>Sequence(s) _____ are missing the <220>Feature and associated headings.
 Use of <220> to <223> is MANDATORY if <213>ORGANISM is "Artificial Sequence" or "Unknown"
 Please explain source of genetic material in <220> to <223> section.
 (See "Federal Register," 6/01/98, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of new Rules)</p> |
| 13 | _____ PatentIn ver. 2.0 "bug" | <p>Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other means to copy file to floppy disk.</p> |

OIFE

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/825,517

DATE: 04/19/2001

TIME: 12:02:25

Input Set : A:\Dyax-161.app

Output Set: N:\CRF3\04192001\I825517.raw

Does Not Comply
Corrected Diskette Needed

3 <110> APPLICANT: Rondon, Isaac J
 4 Ladner, Robert C
 6 <120> TITLE OF INVENTION: BINDING PEPTIDES FOR CARCINOEMBRYONIC ANTIGEN (CEA)
 8 <130> FILE REFERENCE: Sequence Listing DYX-016.1 US
 C--> 10 <140> CURRENT APPLICATION NUMBER: US/09/825,517
 11 <141> CURRENT FILING DATE: 2001-04-03
 13 <150> PRIOR APPLICATION NUMBER: US 09/541345
 14 <151> PRIOR FILING DATE: 2000-04-03
 16 <160> NUMBER OF SEQ ID NOS: 151
 18 <170> SOFTWARE: PatentIn Ver. 2.1
 20 <210> SEQ ID NO: 1
 21 <211> LENGTH: 16
 22 <212> TYPE: PRT
 23 <213> ORGANISM: Artificial Sequence
 25 <220> FEATURE:
 26 <223> OTHER INFORMATION: Description of Artificial Sequence: CEA binding
 27 polypeptide
 29 <220> FEATURE:
 30 <221> NAME/KEY: VARIANT
 31 <222> LOCATION: (1)
 32 <223> OTHER INFORMATION: Xaa is Asn, Asp or is absent
 34 <220> FEATURE:
 35 <221> NAME/KEY: VARIANT
 36 <222> LOCATION: (2)
 37 <223> OTHER INFORMATION: Xaa is Trp
 39 <220> FEATURE:
 40 <221> NAME/KEY: VARIANT
 41 <222> LOCATION: (3)
 42 <223> OTHER INFORMATION: Xaa is Asp, Phe or Val
 44 <220> FEATURE:
 45 <221> NAME/KEY: VARIANT
 46 <222> LOCATION: (5)
 47 <223> OTHER INFORMATION: Xaa is Asn, Glu or Met
 49 <220> FEATURE:
 50 <221> NAME/KEY: VARIANT
 51 <222> LOCATION: (6)
 52 <223> OTHER INFORMATION: Xaa is Asn, Leu, Met or Phe
 54 <220> FEATURE:
 55 <221> NAME/KEY: VARIANT
 56 <222> LOCATION: (7)
 57 <223> OTHER INFORMATION: Xaa is Asp, Gly, Ile, Lys, Phe or Thr
 59 <220> FEATURE:
 60 <221> NAME/KEY: VARIANT
 61 <222> LOCATION: (8)
 62 <223> OTHER INFORMATION: Xaa is Ala, Gln, Gly, Lys or Thr
 64 <220> FEATURE:
 65 <221> NAME/KEY: VARIANT

1-36
 1-36

Gly, add comma
 Gly, Lys or Thr

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/825,517

DATE: 04/19/2001

TIME: 12:02:25

Input Set : A:\Dyax-161.app

Output Set: N:\CRF3\04192001\I825517.raw

```

66 <222> LOCATION: (9)
67 <223> OTHER INFORMATION: Xaa is Arg, Asn, Asp, Glu or Gly
69 <220> FEATURE:
70 <221> NAME/KEY: VARIANT
71 <222> LOCATION: (10)
72 <223> OTHER INFORMATION: Xaa is Gln, Leu or Gly
74 <220> FEATURE:
75 <221> NAME/KEY: VARIANT
76 <222> LOCATION: (11)
77 <223> OTHER INFORMATION: Xaa is Ala, Trp or Tyr
79 <220> FEATURE:
80 <221> NAME/KEY: VARIANT
81 <222> LOCATION: (12)
82 <223> OTHER INFORMATION: Xaa is Ala, Gly, His, Phe, Thr or Val
84 <220> FEATURE:
85 <221> NAME/KEY: VARIANT
86 <222> LOCATION: (14)
87 <223> OTHER INFORMATION: Xaa is Asn, Gln, Phe, Ser or Val
89 <220> FEATURE:
90 <221> NAME/KEY: VARIANT
91 <222> LOCATION: (15)
92 <223> OTHER INFORMATION: Xaa is Arg, Leu, Pro or Ser
94 <220> FEATURE:
95 <221> NAME/KEY: VARIANT
96 <222> LOCATION: (16)
97 <223> OTHER INFORMATION: Xaa is Leu, Ser, Trp or Tyr
99 <400> SEQUENCE: 1 / / / / / / / / / / / / / / / /
W--> 100 Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa
      101 1 5 10 15
104 <210> SEQ ID NO: 2
105 <211> LENGTH: 16
106 <212> TYPE: PRT
107 <213> ORGANISM: Artificial Sequence
109 <220> FEATURE:
110 <223> OTHER INFORMATION: Description of Artificial Sequence: family of
111 preferred CEA binding moieties
113 <220> FEATURE:
114 <221> NAME/KEY: VARIANT
115 <222> LOCATION: (1)
116 <223> OTHER INFORMATION: Xaa is Asn or Asp
118 <220> FEATURE:
119 <221> NAME/KEY: VARIANT Phe?
120 <222> LOCATION: (6)
121 <223> OTHER INFORMATION: Xaa is Ph, Met, Leu or Asn
123 <220> FEATURE:
124 <221> NAME/KEY: VARIANT
125 <222> LOCATION: (7)
126 <223> OTHER INFORMATION: Xaa is Asp, Gly, Ile, Lys, Phe or Thr
128 <220> FEATURE:

```

RAW SEQUENCE LISTING

DATE: 04/19/2001

PATENT APPLICATION: US/09/825,517

TIME: 12:02:25

Input Set : A:\Dyax-161.app

Output Set: N:\CRF3\04192001\I825517.raw

```

129 <221> NAME/KEY: VARIANT
130 <222> LOCATION: (9)
131 <223> OTHER INFORMATION: Xaa is Arg, Asn, Asp, Glu, Gly or Trp
133 <220> FEATURE:
134 <221> NAME/KEY: VARIANT
135 <222> LOCATION: (12)
136 <223> OTHER INFORMATION: Xaa is Ala, Gly, His, Phe, Thr, Tyr or Val
138 <220> FEATURE:
139 <221> NAME/KEY: VARIANT
140 <222> LOCATION: (15)
141 <223> OTHER INFORMATION: Xaa is Arg, Leu, Pro or Ser
143 <220> FEATURE:
144 <221> NAME/KEY: VARIANT
145 <222> LOCATION: (16)
146 <223> OTHER INFORMATION: Xaa is Leu, Ser, Trp or Tyr
148 <400> SEQUENCE: 2
W--> 149 Xaa Trp Val Cys Glu Xaa Xaa Lys Xaa Gln Trp Xaa Cys Asn Xaa Xaa
      150 1 5 10 15
153 <210> SEQ ID NO: 3
154 <211> LENGTH: 10
155 <212> TYPE: PRT
156 <213> ORGANISM: Artificial Sequence
158 <220> FEATURE:
159 <223> OTHER INFORMATION: Description of Artificial Sequence: CEA binding
160 loop
162 <220> FEATURE:
163 <221> NAME/KEY: VARIANT
164 <222> LOCATION: (2)
165 <223> OTHER INFORMATION: Xaa is Asn, Glu or Met
167 <220> FEATURE:
168 <221> NAME/KEY: VARIANT
169 <222> LOCATION: (3)
170 <223> OTHER INFORMATION: Xaa is Asn, Leu, Net or Phe
172 <220> FEATURE:
173 <221> NAME/KEY: VARIANT
174 <222> LOCATION: (4)
175 <223> OTHER INFORMATION: Xaa is Asp, Gly, Ile, Lys, Phe or Thr
177 <220> FEATURE:
178 <221> NAME/KEY: VARIANT
179 <222> LOCATION: (5)
180 <223> OTHER INFORMATION: Xaa is Ala, Gln, Gly, Lys or Thr
182 <220> FEATURE:
183 <221> NAME/KEY: VARIANT
184 <222> LOCATION: (6)
185 <223> OTHER INFORMATION: Xaa is Arg, Asn, Asp, Glu or Gly
187 <220> FEATURE:
188 <221> NAME/KEY: VARIANT
189 <222> LOCATION: (7)
190 <223> OTHER INFORMATION: Xaa is Gln, Gly or Leu

```

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/825,517

DATE: 04/19/2001

TIME: 12:02:25

Input Set : A:\Dyax-161.app

Output Set: N:\CRF3\04192001\I825517.raw

```

192 <220> FEATURE:
193 <221> NAME/KEY: VARIANT
194 <222> LOCATION: (8)
195 <223> OTHER INFORMATION: Xaa is Ala, Trp or Tyr
197 <220> FEATURE:
198 <221> NAME/KEY: VARIANT
199 <222> LOCATION: (9)
200 <223> OTHER INFORMATION: Xaa is Ala, Gly, His, Phe, Thr or Val
202 <400> SEQUENCE: 3
W--> 203 Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys
      204   1           5           10
207 <210> SEQ ID NO: 4
208 <211> LENGTH: 16
209 <212> TYPE: PRT
210 <213> ORGANISM: Artificial Sequence
212 <220> FEATURE:
213 <223> OTHER INFORMATION: Description of Artificial Sequence: CEA binding
214     polypeptide
216 <400> SEQUENCE: 4
217 Asn Trp Val Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asn Ser Tyr
218   1           5           10           15
221 <210> SEQ ID NO: 5
222 <211> LENGTH: 16
223 <212> TYPE: PRT
224 <213> ORGANISM: Artificial Sequence
226 <220> FEATURE:
227 <223> OTHER INFORMATION: Description of Artificial Sequence: CEA binding
228     polypeptide
230 <400> SEQUENCE: 5
231 Asp Trp Val Cys Glu Asn Lys Lys Asp Gln Trp Thr Cys Asn Leu Leu
232   1           5           10           15
235 <210> SEQ ID NO: 6
236 <211> LENGTH: 16
237 <212> TYPE: PRT
238 <213> ORGANISM: Artificial Sequence
240 <220> FEATURE:
241 <223> OTHER INFORMATION: Description of Artificial Sequence: CEA binding
242     polypeptide
244 <400> SEQUENCE: 6
245 Asn Trp Asp Cys Met Phe Gly Ala Glu Gly Trp Ala Cys Ser Pro Trp
246   1           5           10           15
249 <210> SEQ ID NO: 7
250 <211> LENGTH: 16
251 <212> TYPE: PRT
252 <213> ORGANISM: Artificial Sequence
254 <220> FEATURE:
255 <223> OTHER INFORMATION: Description of Artificial Sequence: CEA binding
256     polypeptide
258 <400> SEQUENCE: 7

```

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/825,517

DATE: 04/19/2001

TIME: 12:02:25

Input Set : A:\Dyax-161.app

Output Set: N:\CRF3\04192001\I825517.raw

```

259 Asp Trp Val Cys Glu Lys Thr Thr Gly Gly Tyr Val Cys Gln Pro Leu
260   1           5           10           15
263 <210> SEQ ID NO: 8
264 <211> LENGTH: 16
265 <212> TYPE: PRT
266 <213> ORGANISM: Artificial Sequence
268 <220> FEATURE:
269 <223> OTHER INFORMATION: Description of Artificial Sequence: CEA binding
270     polypeptide
272 <400> SEQUENCE: 8
273 Asn Trp Phe Cys Glu Met Ile Gly Arg Gln Trp Gly Cys Val Pro Ser
274   1           5           10           15
277 <210> SEQ ID NO: 9
278 <211> LENGTH: 16
279 <212> TYPE: PRT
280 <213> ORGANISM: Artificial Sequence
282 <220> FEATURE:
283 <223> OTHER INFORMATION: Description of Artificial Sequence: CEA binding
284     polypeptide
286 <400> SEQUENCE: 9
287 Asp Trp Val Cys Asn Phe Asp Gln Gly Leu Ala His Cys Phe Pro Ser
288   1           5           10           15
291 <210> SEQ ID NO: 10
292 <211> LENGTH: 12
293 <212> TYPE: PRT
294 <213> ORGANISM: Artificial Sequence
296 <220> FEATURE:
297 <223> OTHER INFORMATION: Description of Artificial Sequence: parental
298     domain for design of microprotein display library
300 <220> FEATURE:
301 <221> NAME/KEY: VARIANT
302 <222> LOCATION: (1)..(12)
303 <223> OTHER INFORMATION: amino acid positions 4 and 9 are invariant Cys;
304     all other positions Xaa are varied but not Cys, to
305     provide a library of 2x10(8) different peptides
306     based on the template sequence
308 <400> SEQUENCE: 10
W--> 309 Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa
310   1           5           10
313 <210> SEQ ID NO: 11
314 <211> LENGTH: 11
315 <212> TYPE: PRT
316 <213> ORGANISM: Artificial Sequence
318 <220> FEATURE:
319 <223> OTHER INFORMATION: Description of Artificial Sequence: parental
320     domain for design of microprotein display library
322 <220> FEATURE:
323 <221> NAME/KEY: VARIANT
324 <222> LOCATION: (1)..(11)

```

<210> 108

<211> 16

<212> PRT

<213> Artificial Sequence

see item 12 on Encl Summary Sheet

<400> 108

Asp Trp Ile Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asn Glu Ala

1

5

10

15

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/825,517

DATE: 04/19/2001

TIME: 12:02:26

Input Set : A:\Dyax-161.app

Output Set: N:\CRF3\04192001\I825517.raw

L:10 M:270 C: Current Application Number differs, Replaced Current Application Number
 L:100 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1
 L:149 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2
 L:203 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
 L:309 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:10
 L:331 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11
 L:353 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:12
 L:375 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:13
 L:400 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:14
 L:420 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:15
 L:440 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:16
 L:465 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:17
 L:500 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:18
 L:530 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:19
 L:560 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:20
 L:628 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:23
 L:739 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:29
 L:759 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:30
 L:779 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:31
 L:804 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:32
 L:839 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:33
 L:869 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:34
 L:899 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:35
 L:978 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:36
 L:1981 M:258 W: Mandatory Feature missing, <220> FEATURE:
 L:1981 M:258 W: Mandatory Feature missing, <223> OTHER INFORMATION:
 L:2054 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:110
 L:2144 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:111



Creation date: 10-14-2003
Indexing Officer: HNGUYEN28 - HAO NGUYEN
Team: OIPEBackFileIndexing
Dossier: 09825517

Legal Date: 06-01-2001

No.	Doccode	Number of pages
1	CTMS	2

Total number of pages: 2

Remarks:

Order of re-scan issued on